Edo Vellenga

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

SDG 3 Good Health and Well-being
SDG 7 Affordable and Clean Energy
SDG 9 Industry, Innovation, and Infrastructure
SDG 12 Responsible Consumption and Production

Fingerprint

Dive into the research topics where Edo Vellenga is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
van de Loosdrecht, A. A., Cremers, E. M. P., Alhan, C., Duetz, C., in ’t Hout, F. E. M., Visser-Wisselaar, H. A., Chitu, D. A., Verbrugge, A., Cunha, S. M., Ossenkoppele, G. J., Janssen, J. J. W. M., Klein, S. K., Vellenga, E., Huls, G. A., Muus, P., Langemeijer, S. M. C., de Greef, G. E., te Boekhorst, P. A. W., Raaijmakers, M. H. G. & van Marwijk Kooy, M. & 20 others, Legdeur, M. C., Wegman, J. J., Deenik, W., de Weerdt, O., van Maanen-Lamme, T. M., Jobse, P., van Kampen, R. J. W., Beeker, A., Wijermans, P. W., Biemond, B. J., Tanis, B. C., van Esser, J. W. J., Schaar, C. G., Noordzij-Nooteboom, H. S., Jacobs, E. M. G., de Graaf, A. O., Jongen-Lavrencic, M., Stevens-Kroef, M. J. P. L., Westers, T. M. & Jansen, J. H., Jun-2024, In: Leukemia. 38, p. 840–850 11 p.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access
File
10 Citations (Scopus)

76 Downloads (Pure)
Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study
Hazenberg, C. L. E., de Graaf, A. O., Mulder, R., Bungener, L. B., van Bergen, M. G. J. M., Mulder, A. B., Choi, G., Schuringa, J. J., de Groot, M. R., Vellenga, E., Jansen, J. H., Huls, G. & van Zeventer, I. A., 11-Apr-2023, In: -. 7, 7, p. 1269-1278 10 p.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access
File
7 Citations (Scopus)

154 Downloads (Pure)
Presence of mutant p53 increases stem cell frequency and is associated with reduced binding to classic TP53 binding sites in cell lines and primary AMLs
Gerritsen, M., Hilgendorf, S., Yi, G., Wierenga, A. T. J., Schuringa, J.-J., Martens, J. H. A. & Vellenga, E., Jun-2022, In: Experimental Hematology. 110, p. 39-46 8 p.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access
File
2 Citations (Scopus)

102 Downloads (Pure)
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Löwenberg, B., Pabst, T., Maertens, J., Gradowska, P., Biemond, B. J., Spertini, O., Vellenga, E., Griskevicius, L., Tick, L. W., Jongen-Lavrencic, M., van Marwijk Kooy, M., Vekemans, M.-C., van der Velden, W. J. F. M., Beverloo, B., Michaux, L., Graux, C., Deeren, D., de Weerdt, O., van Esser, J. W. J. & Bargetzi, M. & 28 others, Klein, S. K., Gadisseur, A., Westerweel, P. E., Veelken, H., Gregor, M., Silzle, T., van Lammeren-Venema, D., Moors, I., Breems, D. A., Hoogendoorn, M., Legdeur, M.-C. J. C., Fischer, T., Kuball, J., Cornelissen, J., Porkka, K., Juliusson, G., Meyer, P., Höglund, M., Gjertsen, B. T., Janssen, J. J. W. M., Huls, G., Passweg, J., Cloos, J., Valk, P. J. M., van Elssen, C. H. M. J., Manz, M. G., Floisand, Y. & Ossenkoppele, G. J., 23-Feb-2021, In: Blood. 5, 4, p. 1110-1121 12 p.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access
File
60 Citations (Scopus)

157 Downloads (Pure)
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes
Garcia-Manero, G., Diez-Campelo, M., Vellenga, E., Jacoby, M. A., Merchan, B., Breems, D., Cortelezzi, A., Doronin, V., Gomez, V., Beckers, M., Porta, M. G. D., Varsos, H., Xiu, L., DeAngelis, N., Nnane, I., Rose, E. & van Eygen, K., Apr-2021, In: American Journal of Hematology. 96, 4, p. E111-E114 4 p.
Research output: Contribution to journal › Letter (Research letter) › Academic › peer-review

Open Access
File

1 Citation (Scopus)

89 Downloads (Pure)

Decreased PU.1 and enhanced CITED2 cooperate to maintain self-renewal.
Schepers, H. (Speaker), Korthuis, P. M. (Speaker), Schuringa, J. J. (Speaker), Haan, de, G. (Speaker) & Vellenga, E. (Speaker)
2013
Activity: Talk and presentation › Academic presentation › Academic
Supervision of PhD student Susan de Jonge-Peeters
Vellenga, E. (Supervisor), de Vries, L. (Supervisor) & Kuipers, F. (Supervisor)
16-Feb-2011
Activity: Examination, teaching and supervision › Supervision and examination of PhD students of the UG › Academic
CITED2 modulates differentiation and proliferation of normal and leukemic hematopoietic stem and progenitor cells downstream of PU.1.
Schepers, H. (Speaker), Korthuis, P. M. (Speaker), Schuringa, J. J. (Speaker), Haan, de, G. (Speaker) & Vellenga, E. (Speaker)
10-Dec-2011
Activity: Talk and presentation › Academic presentation › Academic
Supervision of PhD student A. Diepstra
Poppema, S. (Supervisor), Vellenga, E. (Supervisor), te Meerman, G. (Co-supervisor), van den Berg, A. (Co-supervisor) & van Imhoff, G. (Co-supervisor)
7-Nov-2007
Activity: Examination, teaching and supervision › Supervision and examination of PhD students of the UG › Academic
Supervision of PhD student Karen van der Weide
Vellenga, E. (Supervisor), de Vries, L. (Supervisor) & Kuipers, F. (Supervisor)
1-Oct-2006 → 28-Sept-2011
Activity: Examination, teaching and supervision › Supervision and examination of PhD students of the UG › Academic

Edo Vellenga

Personal profile

Expertise related to UN Sustainable Development Goals

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial

Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study

Presence of mutant p53 increases stem cell frequency and is associated with reduced binding to classic TP53 binding sites in cell lines and primary AMLs

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes

Decreased PU.1 and enhanced CITED2 cooperate to maintain self-renewal.

Supervision of PhD student Susan de Jonge-Peeters

CITED2 modulates differentiation and proliferation of normal and leukemic hematopoietic stem and progenitor cells downstream of PU.1.

Supervision of PhD student A. Diepstra

Supervision of PhD student Karen van der Weide

Edo Vellenga

Personal profile

Expertise related to UN Sustainable Development Goals

Fingerprint

Collaborations and top research areas from the last five years

Research output

Activities